@PACEcme

The Physicians’ Academy for Cardiovascular Education aims to help physicians implement scientific findings in clinical practice, to improve patient outcome.

pace-cme.org/
Joined October 2013
  • Tweets2.2K
  • Following494
  • Followers290
148Media
🔥🔥🔥 #ESCPrev2025 Satellite symposium on “Novel Therapies for Managing Patients with #CardioKidneyMetabolic syndrome & #HeartFailure” Together with @RInciardi & @cristina_gavina is now available for your view on @PACEcme Do not miss it! : bit.ly/3GfTT8Q @escardio
1
12
21
1,792
Thanks @PACEcme for covering our #LBCT @escardio #HFA from #FINEARTSHF on the impact of randomization during/shortly post HF hosp on early HF readmission rates. Paper simpub in @JCardFail! Dedicated #REDEFINEHF trial underway to validate these findings. pace-cme.org/congress-covera…
1
6
24
1,676
Additional follow-up shows vutrisiran reduces mortality and CV event risks in ATTR-CM Read more: pace-cme.org/news/additional… #HeartFailure2025 #ATTRCM #CardioTwitter

Additional follow-up shows vutrisiran reduces mortality and CV event risks in ATTR-CM

ESC Heart Failure 2025 – In additional analyses of HELIOS-B, vutrisiran lowered the risks of all-cause and CV mortality at 42 months and rates of CV events at

pace-cme.org
1
1
1
100
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity? @VarunSundaram4 shares the results of the PRAISE-HFrEF study. Watch: pace-cme.org/congress-covera… #HeartFailure2025 #HFrEF #Obesity #PRAISEHFrEF #GLP1RA
1
2
338
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes - great multidisciplinary discussion @PACEcme @HanCardiomd @_antocannata @MarcoMetra pace-cme.org/programs/cme/st…

Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap...

Hyperkalemia is perceived as a barrier to implement guideline-directed medical therapy (GDMT) in patients with cardiorenal disease.

pace-cme.org
7
19
995
Echo essentials for HCM: The heartbeat of diagnosis and treatment Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM Learn more: pace-cme.org/programs/cme/ec… #HCM #cardiomyopathy
124
Single LDL-c, hs-CRP, and Lp(a) measurement predicts long-term MACE risk in healthy Europeans Read more: pace-cme.org/news/single-ldl… #lipids #inflammation #CVD #CardioTwitter #CVrisk

Single LDL-c, hs-CRP, and Lp(a) measurement predicts long-term MACE risk in healthy Europeans

An EPIC-Norfolk study analysis showed one-time screening of LDL-c, hs-CRP, and Lp(a) predicted the risk of incident MACE over 20 years in a European primary

pace-cme.org
75
PACE-CME reports news from the ACC.25 Scientific Session. Follow our news coverage here: pace-cme.org/congress-covera… #ACC25 #cardiology #cardiovascular #diabetes #CVD

ACC.25

PACE-CME.org reports news from the American College of Cardiology Scientific Session 2025 held at Chicago, IL, USA, March 29 - 31, 2025. Find our news cov…

pace-cme.org
95
Icosapent ethyl in post-CABG patients with diabetes Learn more: pace-cme.org/topics/hyperlip… #cardiotwitter #icosapentethyl #CABG #diabetes
1
150
Clinical choices in managing LDL-c: Where do novel therapies fit in? Four experts discuss why LDL-c goal attainment is essential. Which options for LDL-c lowering are available, and where do novel therapies fit in? Learn more: pace-cme.org/programs/cme/cl… #lipids #CardioTwitter
105
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. Watch: pace-cme.org/congress-covera… #CETP #lipids #FH #Obicetrapib #HeFH #AHA24 #BROOKLYN #CardioTwitter
140
DOAC versus VKA after bioprosthetic valve replacement Read more: pace-cme.org/news/doac-versu… #AHA24 #CardioTwitter #Edoxaban #DOAC #VKA #ENBALV
88
No effect of anticoagulation on cognitive decline in patients with AF at low risk of stroke Read more: pace-cme.org/news/effect-ant… #AHA24 #CardioTwitter #AF #Stroke #Cognitivedecline #BRAINAF
75
Promising results with oral Lp(a) inhibitor in phase 2 trial Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin was investigated in patients with elevated Lp(a) levels and high CV risk. Watch: pace-cme.org/congress-covera… #AHA24
90
Tirzepatide reduces HF events in patients with HFpEF and obesity “This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future”, says Milton Packer Watch: pace-cme.org/congress-covera… #AHA2024 #SUMMIT #HF
1
97
Phase 3 study results of the APOC3 siRNA plozasiran in patients with familial chylomicronemia syndrome Learn more: pace-cme.org/topics/hyperlip… #chylomicronemia #plozasiran #FCS #APOC3
1
95
Optimizing care for patients with CKM syndrome: a multidisciplinary approach Learn more: pace-cme.org/programs/cme/op… #CME #CardioTwitter #CKM #Cardiovascular #Kidney #Metabolic
94
Lessons from global survey on Lp(a) levels in CHD Read more: pace-cme.org/news/lessons-gl… #ESCCongress #Lpa #CardioTwitter #CHD #INTERASPIRE
92
β-blocker therapy cannot be safely withdrawn in stable post-MI patients Read more: pace-cme.org/news/b-blocker-… #ESCCongress #ABYSS #postMI #betablocker #Cardiotwitter
1
146
Predicting 30-year CV outcomes in women Paul Ridker talks about the Women’s Health Study, which assessed the predictive value of 3 biomarkers - LDL-c, hsCRP, and Lp(a) - in a single blood sample of 1993 in women. Learn more: pace-cme.org/segment/27016/ #ESCCongress #biomarkers #CVD
1
147
Load more